RenovoRx, Inc. RNXT

RNXT Company Overview

RenovoRx, Inc. is a clinical-stage biopharmaceutical and drug-device combination company focused on targeted oncology therapies. The company develops localized therapeutic delivery technologies intended to improve treatment precision while reducing systemic toxicity associated with conventional intravenous chemotherapy. RenovoRx primarily operates in the oncology and interventional medicine sectors, with an emphasis on difficult-to-treat solid tumors, including pancreatic cancer and bile duct cancer.

The company’s principal platform is the RenovoCath delivery system, a proprietary trans-arterial therapy device designed to enable regional administration of chemotherapeutic agents directly to tumors through the arterial vasculature. RenovoRx’s strategy centers on combining established oncology drugs with its targeted delivery approach to potentially improve therapeutic concentration at tumor sites while limiting exposure to healthy tissue. The company evolved from earlier development-stage efforts focused on regional cancer therapy and has increasingly concentrated on advancing clinical programs and regulatory pathways for its lead oncology applications.